⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868247 | 1.00 | — | — | |
| SCHEMBL7075603 | 0.82 | — | — | |
| SCHEMBL7079014 | 0.82 | — | — | |
| SCHEMBL14868264 | 0.78 | KDM1A (0.44) | — | |
| SCHEMBL15100494 | 0.77 | KDM1A (0.37) | — | |
| SCHEMBL14868270 | 0.77 | NOS1 (0.43) | — | |
| SCHEMBL28169763 | 0.76 | NOS1 (0.39) | — | |
| SCHEMBL10961889 | 0.75 | — | — | |
| SCHEMBL10961883 | 0.75 | — | — | |
| SCHEMBL14868276 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8029609-B2 | Ejection liquid, ejection device, ejection cartridge, and method of making droplets from liquid | CANON KABUSHIKI KAISHA (JP) | 2011-10-04 | — | — | US | claimed |
| CN-118119670-A | Room temperature curable organopolysiloxane composition, adhesive, sealant, and coating agent | 信越化学工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| US-11993637-B2 | Modified FGF-21 polypeptides with non-naturally encoded amino acids | AMBRX, INC. | 2024-05-28 | — | — | US | disclosed |
| CN-107501407-B | Modified FGF-21 polypeptides and uses thereof | AMBRX公司 | 2022-03-18 | — | — | CN | disclosed |
| US-10961291-B2 | Modified FGF-21 polypeptides and their uses | AMBRX, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200031894-A1 | MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES | AMBRX, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10377805-B2 | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses | AMBRX, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180298073-A1 | MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES | AMBRX, INC. | 2018-10-18 | — | — | US | disclosed |
| US-9975936-B2 | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170096463-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20060252686-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-20060205727-A1 | Combination therapy for endothelial dysfunction, angina and diabetes | HONG KONG NITRIC OXIDE LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| US-20060003981-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A | 2006-01-05 | — | — | US | disclosed |
| US-20050282794-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A | 2005-12-22 | — | — | US | disclosed |
| US-20050233946-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A | 2005-10-20 | — | — | US | disclosed |
| US-20050233947-A1 | Combinations of chromium or vanadium with antidiabetics | FINE STUART A | 2005-10-20 | — | — | US | disclosed |
| US-20050187144-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A (US) | 2005-08-25 | — | — | US | disclosed |
| US-6852760-B1 | Compositions and methods for treatment for glucose metabolism disorders | AKESIS PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040109891-A1 | Sustained release formulations of metformin | PENWEST PHARMACEUTICALS COMPANY | 2004-06-10 | — | — | US | disclosed |
| US-6376549-B1 | BIOAVAILABILITY; SYNERGISTIC MIXTURE | AKESIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |